Pegizex 3750IU Injection

About

Pegizex 3750IU Injection contains Pegfilgrastim, a long-acting form of recombinant human granulocyte colony-stimulating factor (G-CSF). Its primary function is to stimulate the bone marrow to produce, mature, and release neutrophils, which are vital white blood cells responsible for combating bacterial infections. This medication is specifically designed to mitigate the risk of febrile neutropenia, a severe complication characterized by fever and a dangerously low neutrophil count, frequently observed in cancer patients undergoing myelosuppressive chemotherapy. The pegylation technology extends the drug's half-life, enabling a single administration per chemotherapy cycle, thereby offering enhanced convenience and adherence compared to daily G-CSF regimens. It plays a crucial role in supportive cancer care.

Uses

• Prevention of chemotherapy-induced febrile neutropenia
• Reduction of infection risk in cancer patients
• Stimulation of neutrophil recovery after chemotherapy
• Supportive care during myelosuppressive treatments

Directions For Use

Administered subcutaneously, typically once per chemotherapy cycle, at least 24 hours after cytotoxic chemotherapy.

Benefits

• Significantly lowers the incidence of febrile neutropenia.
• Reduces the risk of serious infections.
• Facilitates timely administration of chemotherapy cycles.
• Offers the convenience of a single dose per cycle.
• Enhances patient safety during cancer treatment.
• Promotes rapid bone marrow recovery.

Side Effects

• Bone pain
• Myalgia (muscle pain)
• Headache
• Fatigue
• Nausea
• Injection site reactions
• Splenomegaly (enlarged spleen)
• Thrombocytopenia
• Leukocytosis
• Allergic reactions
• Acute respiratory distress syndrome (rare)
• Glomerulonephritis (rare)

Safety Measures

• Alcohol - No specific contraindication, but general health recommendations apply. May not interact directly with the drug.
• Pregnancy - Use only if potential benefits outweigh risks. Limited human data; animal studies are inconclusive. Consult a physician.
• Breastfeeding - Unknown if excreted in human milk. Exercise caution and consult a healthcare provider before use.
• Liver - No specific dose adjustment is typically required for patients with hepatic impairment.
• Kidney - No specific dose adjustment is typically required for patients with renal impairment.
• Lung - Rarely, serious pulmonary adverse reactions, including interstitial pneumonia, can occur; monitor for new or worsening respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.